Hepatorenal syndrome: Definition, pathophysiology, and intervention

Critical Care Clinics

Volumn 18, Issue 2, 2002, Pages 345-373

  Briglia, Andrew E ^a   Anania, Frank A ^a  

^a UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CALCIUM ANTAGONIST; DAZOXIBEN; DEMECLOCYCLINE; DIURETIC AGENT; DOPAMINE; FUROSEMIDE; LACTULOSE; MIDODRINE; NONSTEROID ANTIINFLAMMATORY AGENT; NORADRENALIN; OCTREOTIDE; ORNIPRESSIN; OZAGREL; PROPRANOLOL; PROSTAGLANDIN SYNTHASE INHIBITOR; SPIRONOLACTONE; THROMBOXANE A2; VASOPRESSIN DERIVATIVE; URINARY TRACT AGENT;

ASCITES; CLINICAL TRIAL; DIAGNOSTIC APPROACH ROUTE; FLUID BALANCE; HEMODIALYSIS; HEPATORENAL SYNDROME; HUMAN; HYPONATREMIA; LIVER FAILURE; LIVER TRANSPLANTATION; PATHOPHYSIOLOGY; PERITONEUM VEIN SHUNT; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; REVIEW; SODIUM BALANCE; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; DETOXIFICATION; METHODOLOGY; NOMENCLATURE; PLASMAPHERESIS; RENAL REPLACEMENT THERAPY;

ASCITES; HEPATORENAL SYNDROME; HUMANS; LIVER TRANSPLANTATION; PERITONEOVENOUS SHUNT; PLASMA EXCHANGE; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC; RENAL AGENTS; RENAL DIALYSIS; SORPTION DETOXIFICATION; TERMINOLOGY;

EID: 0036014090     PISSN: 07490704     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0749-0704(01)00003-3     Document Type: Article

References (179)

1. Use of extracorporeal ascites dialysis in combined hepatic and renal failure
2. Pathogenesis of hepatorenal syndrome
3. Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites
4. Reversal of type 1 hepatorenal syndrome with the administration of midodrine octreotide
5. Dialysis disequilibrium syndrome: Current concepts on pathogenesisand prevention
6. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis
7. Renal failure in cirrhosis and liver transplantation
8. Clinical effects of a sorbent suspension dialysis system in treatment of hepatic coma (the BioLogic-DT)
9. Clinical trials of the BioLogic-HD. Automated single access, sorbent-based dialysis
10. Hepatorenal syndrome. New perspectives in pathogenesis and treatment
11. Effects of bicarbonate-and lactate-buffered replacement fluids on cardiovascular outcome in CVVH patients
12. Effects of propranolol on renal blood flow and renal function in patients with cirrhosis
13. Hepatorenal syndrome: Definition, pathophysiology, clinical features and management
14. Practical recommendations for the treatment of ascites and its complications
15. Continuous arteriovenous haemodiafiltration in the critically ill: Influence on major nutrient balances
16. Effect of continuous venovenous hemofiltration with dialysis on hormone and catecholamine clearance in critically ill patients with acute renal failure
17. Response to dopamine hydrochloride in the hepatorenal syndrome
18. Hepatorenal syndrome and ascites - Questions and answers
19. Effects of serial resin hemoperfusion in fulminant hepatic failure
20. Bile acids, oxidative stress, and renal function in biliary obstruction
21. Use of diuretics in the treatment of cirrhotic ascites
22. New method of extracorporeal concentration of ascitic fluid as a treatment of refractory ascites
23. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: A phase II strudy
24. Acute renal failure in the intensive care unit. Therapy overview, patient risk stratification, complications of renal replacement and special circumstances
25. Comparison of spontaneous ascites filtration reinfusion with total paracentesis with intravenous albumin infusion in cirrhotic patients with tense ascites
26. Spontaneous dialytic ultrafiltration with intraperitoneal reinfusion of the concentrate versus large paracentesis in cirrhotic patients with intractable ascites a randomized study
27. Activation of the tissue factor pathway occurs during continuous venovenous hemofiltration
28. Renal failure associated with demeclocycline in cirrhosis
29. Terlipressin may influence the outcome of hepatorenal syndrome complicating alcoholic hepatitis
30. Immunological considerations of the uremic and dialyzed patient
31. The hemodialysis membranes: A historical perspective, current state and future prospect
32. Hepatocirculatory failure: Diverse pathogeneses deserve diverse therapies
33. Systemic vasoconstrictor and renal vasodilator effects of PLV2 (Octapressin) in man
34. Is there a role for continuous renal replacement therapies in patients with liver and renal failure?
35. Effect of renal replacement therapy on patients with combined acute renal and fulminant hepatic failure
36. Rebound surges of intracranial pressure as a consequence of forced ultrafiltration used to control intracranial pressure in patients with severe hepatorenal failure
37. Changes in intracranial pressure during haemofiltration in oliguric patients with grade hepatic encephalopathy
38. Membrane biocompatibility: Effects on cardiovascular stability in patients on hemofiltration
39. Continuous arteriovenous haemofiltration in patients with hepatic encephalopathy and renal failure
40. Haemofiltration in patients with fulminant hepatic failure
41. Amino acid losses during continuous high-flux hemofiltration in the critically ill patient
42. Amino acid losses during haemofiltration
43. Changes in intracranial pressure during machine and continuous haemofiltration
44. Amino acid clearances and daily losses in patients with acute renal failure treated by continuous arteriovenous hemodialysis
45. Cytokine removal during continuous hemofiltration in septic patients
46. Impact of continuous renal replacement therapies on metabolism
47. Hepatorenal syndrome without avid sodium retention
48. Reversal of hepatorenal syndrome with the combination of norepinephrine and dopamine
49. Renal failure in liver disease
50. Combined ascitic-fluid and furosemide infusion in the management of ascites
51. Renal failure and dialysis therapy in children with hepatic failure in the perioperative period of orthotopic liver transplantation
52. Hepatorenal syndrome
53. Renal sodium handling in liver disease
54. Continuous arterio-venous ultrafiltration in cirrhotic patients with ascites or renal failure
55. Continuous arterio-venous ultrafiltration in the management of the renal complications of liver disease
56. Hepatorenal syndrome: Emerging perspectives
57. Hepatorenal syndrome: Emerging perspectives of pathophysiology and therapy
58. The hepatorenal syndrome: Newer perspectives
59. Calcium antagonists and renal protection. Current status and future perspectives
60. Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure
61. Treatment of hepatic coma and hepatorenal syndrome: Mechanism of action of L-Dopa and Aramine
62. Successful application of extracorporeal liver perfusion: A technology whose time has come
63. Glucose dynamics during continuous hemodiafiltration and total parenteral nutrition
64. Amino acid loss and plasma concentration during continuous hemodiafiltration
65. Hepatorenal syndrome. Long-term treatment with terlipressin as a bridge to liver transplantation
66. Current management of the complications of cirrhosis and portal hypertension: Variceal hemorrhage, ascites, and spontaneous bacterial peritonitis
67. Hepatorenal syndrome and ascites - An introduction
68. Effects of OKY 046, a thromboxane-synthase inhibitor, on renal function in nonazotemic cirrhotic patients with ascites
69. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites
70. Hepatorenal syndrome
71. Pathophysiology of renal dysfunction in cirrhosis
72. Ascites and hepatorenal syndrome: Pathogenesis and treatment strategies
73. Continuous arterio-venous haemodialysis during emergency hepatic retransplantation
74. Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome: Experience in 300 patients
75. Impact of pretransplant renal function on survival after liver transplantation
76. Acute changes in renal excretion of water and solute in patients with Laennec's Cirrhosis, induced by the administration of the pressor amine, metaraminol
77. Circulatory disturbance and renal dysfunction in liver disease and in obstructive jaundice
78. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion
79. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine
80. Which amino-acids do serum and hemofiltrate of critically ill patients with acute renal failure contain?
81. Terlipressin in the treatment of hepatorenal syndrome (HRS): A double blind cross-over study
82. Effect of the dialysis membrane in the treatment of patients with acute renal failure
83. Extracorporeal dialysis of ascites. A new technique
84. Hemofiltration in human sepsis: Evidence for elimination of immunomodulatory substances
85. Improvement in renal function in hepatorenal syndrome with N-acetylcysteine
86. Use of sorbent columns and haemofiltration in fulminant hepatic failure
87. Evaluation of the BioLogic-DT sorbent-suspension dialyser in patients with fulminant hepatic failure
88. Amino acid losses during hemodialysis: Effects of high-solute flux and parenteral nutrition in acute renal failure
89. Amino acid and albumin losses during hemodialysis
90. Continuous haemoperfusion for fulminant hepatic failure
91. Haemodialysis-membrane biocompatibility and mortality of patients with dialysis-dependent acute renal failure: A prospective randomised multicentre trial
92. Continuous arteriovenous hemofiltration. A report of six months' experience
93. Continuous renal replacement therapy (CRRT) in the intensive care unit
94. Extracorporeal blood purification in the management of patients with hepatic failure
95. Risk factors and outcome of 107 patients with decompensated liver disease and acute renal failure (including 26 patients with hepatorenal syndrome): The role of hemodialysis
96. Amino acid losses and nitrogen balance during slow diurnal hemodialysis in critically ill patients with renal failure
97. Thromboxane-receptor blockade increases water diuresis in cirrhotic patients with ascites
98. Arachidonic acid derivatives and renal function in liver cirrhosis
99. Large-volume paracentesis versus dialytic ultrafiltration in the treatment of cirrhotic ascites
100. Transjugular intrahepatic portacaval stent shunts in patients with renal insufficiency
101. Simultaneous determination of cardiac output and renal function in patients with Laennec's cirrhosis during the administration of the pressor amine, metaraminol
102. Spontaneous ascites filtration and reinfusion (SAFR) in cirrhotic patients
103. Spontaneous ascites filtration and reinfusion (SAFR) as ambulatory chronic treatment for hepatorenal syndrome
104. Hepatorenal reflex regulating kidney function
105. New clues to the pathophysiology of hepatorenal failure
106. Continuous arteriovenous hemofiltration in the critically ill patient. Clinical use and operational characteristics
107. Transjugular intrahepatic portosystemic shunts: Comparison with paracentesis in patients with cirrhosis and refractory ascites: A randomized trial
108. Accumulation of Bradykinin formed by the AN69- or PAN 17DX membrane is due to the presence of an ACE-Inhibitor in Vitro
109. Beneficial effect of 8-omithin vasopressin on renal dysfunction in decompensated cirrhosis
110. Ornipressin in the treatment of functional renal failure in decompensated liver cirrhosis. Effects on renal hemodynamics and atrial natriuretic factor
111. Plasmapheresis with plasma exchange in hepatic coma. II. Fulminant viral hepatitis as a systemic disease
112. Plasmapheresis with plasma exchange in hepatic coma. Methods and results in five patients with acute fulminant hepatic necrosis
113. Plasmapheresis in hepatic coma
114. Liver disease, aminoglycoside antibiotics and renal dysfunction
115. Continuous venovenous hemodialysis treatment in critically ill patients after liver transplantation
116. Continuous renal replacement therapies: An update
117. Peritoneal dialysis in end-stage renal disease patients with preexisting chronic liver disease and ascites
118. Pathogenesis of water and sodium retention in cirrhosis
119. Continuous removal of middle molecules by hemofiltration in patients with acute liver failure
120. Effects of lactate-buffered and lactate-free dialysate in CAVHD patients with and without liver dysfunction
121. Regional citrate anticoagulation for continuous arteriovenous hemodialysis in critically ill patients
122. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: Results of a prospective, randomized, controlled clinical trial
123. Extracorporeal detoxification using the molecular adsorbent recirculating system for critically ill patients with liver failure
124. Uptake of glucose during continuous arteriovenous hemofiltration
125. Plasma endothelin immuno reactivity in liver disease and the hepatorenal syndrome
126. Increased risk of renal dysfunction due to interaction of liver disease and aminoglycosides
127. The peritoneovenous shunt: Expectations and reality
128. Removal of endotoxin and cytokines by adsorbents and the effect of plasma protein binding
129. Profound hypercalcemia in continuous veno-venous hemofiltration dialysis with trisodium citrate anticoagulation and hepatic failure
130. The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites
131. Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure
132. Hepatic failure coma (HFC) treated by polyacrylonitrile membrane (PAN) hemodialysis (HD)
133. Anaphylactoid reactions in hemodialysis patients treated with the AN69 dialyzer
134. Dialysis therapy
135. Dialysis, hemofiltration, and other extracorporeal techniques in the treatment of the renal complications of liver disease
136. Hepatorenal syndrome
137. Peritoneal dialysis therapy for patients with liver and renal failure with ascites
138. Effects of endothelin1 on renal function in humans: Implications for physiology and pathophysiology
139. The effects of dialytic ultrafiltration and peritoneal reinfusion in the management of diuretic resistant ascites
140. Postdilution hemofiltration in the management of acute hepatic failure: A pilot study
141. Hepatoactive substances eliminated by continuous venovenous hemofiltration in acute renal failure patients
142. Ascites and hepatorenal syndrome: Pathophysiology and management
143. Continuous renal replacement therapies for the treatment of acute renal failure in intensive care patients
144. Control of cerebral oedema by total hepatectomy and extracorporeal liver support in fulminant hepatic failure
145. Development of a hybrid bioartificial liver
146. A hepatorenal depressor reflex: A possible clue to the pathogenesis of the hepatorenal syndrome
147. Continuous arteriovenous haemodialysis during emergency hepatic retransplantation: Two case reports
148. Acute dialytic support in patients with end stage liver disease awaiting liver transplantation
149. Intraoperative continuous arterio-venous hemofiltration (CAVH) - A method to diminish fluid sequestration during liver transplant operations
150. Classical and alternative indications for continuous renal replacement therapy
151. Biocompatible membranes in acute renal failure: Prospective case-controlled study
152. Peripheral arterial vasodilation hypothesis: A proposal for the initiation of renal sodium and water retention in cirrhosis
153. Inhibition of rat brain Na+,K+-ATPase activity by serum from patients with fulminant hepatic failure
154. Renal failure in patients with cirrhosis of the liver: Part i. Clinical and pathologic characteristics
155. Renal failure in patients with cirrhosis of the liver: Part ii. Factors influencing maximal urinary flow rate
156. Urinary sodium and chloride during renal salt retention
157. The role of transjugular intrahepatic portosystemic shunt for treatment of portal hypertension and its complications: A conference sponsored by the National Digestive Diseases Advisory Board
158. Experiences in the treatment of fulminant hepatic failure by conservative therapy, charcoal haemoperfusion, and polyacrylonitrile haemodialysis
159. Renal function in obstructive jaundice in man: Cholangiocarcinoma model
160. Amelioration of hepatorenal syndrome with selective endothelin-A antagonist
161. Treatment of acute liver failure with hemodetoxification techniques
162. Natriuretic effect of an adenosine-1 receptor antagonist in cirrhotic patients with ascites
163. Concomitant renal and hepatic failure treated by polyacrylonitrile membrane hemodialysis
164. Drug dosing in acute renal failure: The role of renal replacement therapy in altering drug pharmacokinetics
165. Extracorporeal liver assist in the treatment of fulminant hepatic failure
166. Terlipressin plus albumin infusion: An effective and safe therapy of hepatorenal syndrome
167. Bradykinin is a mediator of anaphylactoid reactions during hemodialysis with AN69 membranes
168. Cerebral blood flow and metabolism in fulminant liver failure
169. Dopamine in the hepatorenal syndrome
170. Amino acid losses during hemodialysis with infusion of amino acids and glucose
171. Therapy for hepatorenal syndrome
172. Digoxin-like immunoreactive substances in severe acute liver disease due to viral hepatitis and paracetamol overdose
173. Improvement of renal failure with repeated head-out water immersions in patients with hepatorenal syndrome associated with alcoholic hepatitis
174. Development of reliable artificial liver support (ALS) - Plasma exchange in combination with hemodiafiltration using high-performance membranes
175. Development of a reliable artificial liver support. Plasma exchange in combination with hemodiafiltration using "high performance membranes"
176. Gentamicin and gram-negative bacteremia. A synergism for the development of experimental nephrotoxic acute renal failure
177. Therapeutic trial of thromboxane synthesis inhibition in the hepatorenal syndrome